

DEVELOPMENT OF RNA INTERFERENCE ANTIVIRAL THERAPEUTICS

**Antonin de Fougères, Alynam Research Team, Alynam Pharmaceuticals, Inc.,
300 3rd St., Cambridge, MA**

Novel therapies based on short interfering RNA (siRNA) duplexes have tremendous potential to treat diseases by silencing the expression of otherwise non-druggable proteins. Active RNA interference (RNAi) Therapeutics can be identified in weeks to months making them particularly well suited as antiviral drugs for existing and newly emerging threats. An RNAi Therapeutic for the treatment of respiratory syncytial virus (RSV) infection is now in clinical trials, and an RNAi Therapeutic for treatment of pandemic influenza is in advanced development. In collaboration with USAMRIID and NIAID, Alynam is developing an RNAi Therapeutic designed to target all pathogenic strains of Ebola virus.